Aida Santaolalla
About Aida Santaolalla
Aida Santaolalla is a Real World Evidence Senior Manager with extensive experience in cancer epidemiology and molecular profiling. She currently holds positions at Karolinska Institutet, King's College London, and UCL, focusing on prostate cancer and haematological malignancies.
Work at Kite Pharma
Aida Santaolalla serves as the Real World Evidence Senior Manager at Kite Pharma since 2024. In this role, she focuses on molecular profiling for prostate cancer and haematological malignancies. Her work involves utilizing data to enhance understanding of cancer characteristics and treatment outcomes.
Current Positions at Academic Institutions
Aida Santaolalla holds multiple honorary positions at prestigious institutions. She has been an Honorary Research Fellow at Karolinska Institutet since 2020, and at King's College London since 2024. Additionally, she serves as an Honorary Lecturer at UCL since 2023. Her roles involve contributing to research in cancer epidemiology and data science.
Previous Experience at King's College London
Aida Santaolalla has extensive experience at King's College London, where she worked in various capacities. She was the Lead of the Molecular Cancer Epidemiology Track in TOUR from 2022 to 2024. Prior to that, she served as a Senior Data Scientist and Senior Research Fellow from 2018 to 2024, and as Clinical Database Manager and Prostate Cancer Biobank Coordinator from 2011 to 2018.
Education and Expertise
Aida Santaolalla holds a Doctor of Philosophy (Ph.D.) in Cancer Epidemiology and Biostatistics from King's College London, completed between 2013 and 2018. She also earned a Master's Degree in Bioinformatics for Health Science from Universitat Pompeu Fabra from 2005 to 2007. Her educational background supports her expertise in molecular profiling and cancer research.
Research Contributions
Aida Santaolalla has contributed to significant research initiatives. She collaborates with the MRC Stratified Medicine Consortium Re-IMAGINE to study mpMRI's role in prostate cancer diagnosis. Additionally, she has worked with the haemato-oncology team at Guys’ Hospital to develop early detection biomarkers for Myeloproliferative Neoplasms and Acute Myeloid Leukaemia using mass cytometry data.